Comparison of efficacy and safety of Tramadol, Paroxetine and placebo in treatment of life long premature ejaculatio
Phase 3
- Conditions
- Premature ejaculation.Premature ejaculation
- Registration Number
- IRCT201008304582N2
- Lead Sponsor
- rology Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 150
Inclusion Criteria
at least one year of their marriage is past; to be between 18-50 years of age; have the possibility of intercourse at least once a week, ability to read and write
Exclusion criteria: People who have a history of mental diseases, a physical illness such as diabetes and liver disease, alcohol or drug abuse, a history of surgery that has been effective on sexual function; history of endocrine disease, prostatitis; history of paroxetine and tramadol during the last 3 months
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intravaginal ejaculation latency time (IELT). Timepoint: Baseline and 3 months after treatment. Method of measurement: Ask the patient based on the PEP Questionnaire.
- Secondary Outcome Measures
Name Time Method